Faecalibacterium prausnitzii EB-FPDK11 Strain for Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, liver diseases, and metabolic diseases are inadequate, and there is a need for safe and effective strains that can be used to prevent or treat these conditions.
Innovation Solution
The development of a novel Faecalibacterium prausnitzii strain EB-FPDK11, characterized by its 16S rRNA sequence, which is used in pharmaceutical and food compositions to inhibit inflammation, treat liver diseases, and manage metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for inflammatory diseases, liver diseases, and metabolic diseases are used, then therapeutic effects are achieved, but adverse side effects occur and treatment adequacy is insufficient
Solution Approach 1:
The patent introduces Faecalibacterium prausnitzii as a biological intermediary substance that mediates between the patient's body and the disease condition. This probiotic strain acts as a safe intermediary that modulates the immune system and reduces inflammation without the harmful side effects of conventional pharmaceutical treatments, thereby resolving the contradiction between therapeutic effectiveness and safety
Solution Approach 2:
The patent changes the fundamental parameter of treatment from synthetic pharmaceuticals to live bacterial cultures and their metabolites. By using F. prausnitzii and its postbiotic products, the treatment paradigm shifts to a biologically-compatible approach that maintains therapeutic efficacy while eliminating adverse side effects associated with conventional medications
2Reliability
If new therapeutic strains are developed, then therapeutic benefits are improved, but development complexity and characterization requirements increase
Solution Approach 1:
The patent replaces complex mechanical and chemical characterization methods with molecular biological techniques, specifically 16S rRNA gene sequencing. This substitution allows for precise identification and characterization of the F. prausnitzii strain through genetic markers, simplifying the overall characterization process while maintaining high reliability in strain identification and therapeutic benefit validation
Data Source
Figure 1A~2
Figure 3~4
Figure 5~6
AI summary
The present disclosure relates to a novel Faecalibacterium prausnitzii EB-FPDK11 strain and the use thereof. Administration of a composition containing at least one selected from the group consisting of the F. prausnitzii EB-FPDK11 strain, a culture of the strain, a lysate of the strain, and an extract of the strain has the effects of preventing, ameliorating and treating inflammatory disease, liver disease or metabolic disease.